RAVICTI® provides long-term normalised ammonia levels

RAVICTI® (glycerol phenylbutyrate) is the only UCD treatment that has been shown to provide sustained ammonia control in both short term (2 weeks) and long-term (12 months) in prospective studies.¹

Favourable pharmacokinetics of RAVICTI result in a clinically meaningful and statistically significant difference in ammonia control, with demonstrated overnight control, a potentially vulnerable period for UCD patients.

In the paediatric period, in which patients are particularly vulnerable to experiencing their first HAC, RAVICTI demonstrated a statistically significant reduction in mean normalised ammonia levels and sustained long-term control.

RAVICTI has been associated with fewer hyperammonaemic crises vs NaPBA

The rate and severity of HACs are associated with worsened neurocognitive outcomes. RAVICTI demonstrated a statistically significant reduction in the number of HACs and hospitalisations compared to pre-study treatment with NaPBA.

References:
1. Summary of Product Characteristics RAVICTI.
2. Diaz GA et al. Hepatology. 2013;57(6):2171–2179.
3. Berry S et al. Molecular Genetics and Metabolism 2014;112(1):17–24.
4. Kent JD and Holt RJ, Neuropsychiatry. 2016;7(1):578–583.